Dr. Reddy to introduce Merck’s anti-viral drug to Indian markets, gets the nod from DCGI
Dr. Reddy’s Laboratories, on Tuesday, announced that it has received emergency-use authorization from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug Molnupiravir capsules for the treatment of adult patients with COVID-19.
Commenting on the development, G.V. Prasad, Co-Chairman and Managing Director, Dr. Reddy’s, said: “Molnupiravir is a continuation of our constant effort since the start of the pandemic to ensure access to every possible treatment option against COVID-19 from prevention to mild, moderate and severe disease for patients in India and around the world.”
The pharma firm has made adequate capacity preparations to ensure that it is able to help patients in India as well as inpatient populations in need around the world and will soon launch its molnupiravir capsules 200mg under the brand name ‘Molflu’ across India.
Prasad added, “The approval to launch molnupiravir is an important development not only as a treatment option, but also for the collaborative manner in which Indian pharma companies came together. Throughout the pandemic, we have sought to create diverse collaborations and partnerships to meet unmet medical needs of as many patients as possible globally.”
The patients, having more than 93% oxygen saturation level and a high risk of progression of the disease including hospitalization or death, will be administered the medicine.
Dr. Reddy’s, earlier this year, signed a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries.
See the tweet: